C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment o…
$2.76-0.36%
报价 2026-11-13
市值
$362.4M
EV
$327.6M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -40.9%
$1.71$4.67
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CCCCC4 Therapeutics, Inc. | $362.4M | -0.4% | -4.3% | 94.9% | – | – | – | |
| OABIOmniAb, Inc. | $716.2M | -0.8% | +91.2% | 63.6% | – | – | 312.2x | |
| PEPGPepGen Inc. | $302M | -13.5% | +837.5% | 0% | – | – | – | |
| ARMPArmata Pharmaceuticals, Inc. | $143.9M | +4.0% | +13.3% | 68.2% | – | – | – | |
| CDXSCodexis, Inc. | $127.1M | +21.1% | +10.1% | 79.5% | – | – | – | |
| MOLNMolecular Partners AG | $112.7M | -2.3% | – | 0% | – | – | – | |
| IMDXInsight Molecular Diagnostics Inc. | $70M | -7.4% | -18.8% | 11.2% | – | – | – | |
| MISTMilestone Pharmaceuticals Inc. | $64.7M | -20.6% | – | 94.6% | – | – | – | |
| 同行中位数 | – | – | +13.3% | 63.6% | – | – | 312.2x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。